Recently two new selective RET inhibitors, selpercatinib and pralsetinib, have shown significant efficacy in treating patients with RET gene rearrangements and activating mutations, in both lung and thyroid cancers (Wirth et al., 2020; Drilon et al., 2020). The gene discussed is RET; the disease is thyroid gland carcinoma.